ArticleRadiation oncology (London, England)2020
A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy.
Article in Radiation oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Breast cancer radiotherapy and the risk of lung injury: Advances and perspectives.Advances in radiotherapy & nuclear medicine · 2026Article
- Dose Constraints in Carbon-Ion Radiation Therapy to Minimize the Risk of Pectoral Myositis.International journal of particle therapy · 2025Article
- Value of Carbon-Ion Radiation Therapy for Breast Cancer.International journal of particle therapy · 2024Review
- Dosimetric analysis of six whole-breast irradiation techniques in supine and prone positions.Scientific reports · 2024Article
- Changes in Intratumor Blood Flow After Carbon-Ion Radiation Therapy for Early-Stage Breast Cancer.International journal of particle therapy · 2024Article
- Definitive ablative stereotactic partial breast irradiation in early stage inoperable breast cancer.Journal of cancer research and clinical oncology · 2023Article
- Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects.Cancers · 2023Review
- Particle radiotherapy for breast cancer.Frontiers in oncology · 2023Review
- Recent advances progress in radiotherapy for breast cancer after breast-conserving surgery: a review.Frontiers in oncology · 2023Review
- Basic and translational research on carbon-ion radiobiology.American journal of cancer research · 2023Review
- Definitive radiotherapy with stereotactic or IMRT boost with or without radiosensitization strategy for operable breast cancer patients who refuse surgery.Journal of radiation research · 2022Article
- Particle Therapy for Breast Cancer.Cancers · 2022Review
- Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.Breast cancer : basic and clinical research · 2022Article
- Particle Therapy for Breast Cancer: Benefits and Challenges.Frontiers in oncology · 2021Review
- Dosimetric Comparison of Particle Radiotherapy and Photon VMAT for Left-Sided Breast Cancer Post Breast-Conserving Surgery.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeOur institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome of cases treated outside clinical trial up to May 2020. MATERIALS AND
methodsEligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy [relative biological efficacy (RBE)]. After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE).
resultsBetween April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbonion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results.
conclusionsThe time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbonion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.